Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Joly-Guillou
Marie-Laure
ML
Bacteriology department, Universitary Hospital, (Larrey St), Angers (49000), France. mljoly-guillou@chu-angers.fr
Kempf
Marie
M
Cavallo
Jean-Didier
JD
Chomarat
Monique
M
Dubreuil
Luc
L
Maugein
Jeanne
J
Muller-Serieys
Claudette
C
Roussel-Delvallez
Micheline
M
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016470:Bacteremia / Q000382:microbiology; D005602:France; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D000077731:Meropenem; D008826:Microbial Sensitivity Tests / Q000379:methods; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010538:Peritonitis / Q000382:microbiology; D010878:Piperacillin / Q000494:pharmacology; D000077725:Piperacillin, Tazobactam Drug Combination; D018410:Pneumonia, Bacterial / Q000382:microbiology; D013845:Thienamycins / Q000494:pharmacology*; D014946:Wound Infection / Q000382:microbiology
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077725:Piperacillin, Tazobactam Drug Combination; D015378:Imipenem; D010397:Penicillanic Acid; D000077731:Meropenem; D010878:Piperacillin